TDMS Study 05107-06 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
NICKEL SUBSULFIDE
NTP Experiment-Test: 05107-06 Report: PEIRPT05
Study Type: CHRONIC Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
Facility: Lovelace Inhalation Toxicology Research Institute
Chemical CAS #: 12035722
Lock Date: 10/14/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 20 60 20 60 20
Scheduled Sacrifice 2 18 20 2 18
Early Deaths
Moribund Sacrifice 14 15 11 2
Natural Death 8 11 9
Survivors
Terminal Sacrifice 36 34 38
Other 2
Animals Examined Microscopically 58 10 60 10 58 12
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (53) (5) (51) (5) (51) (7)
Intestine Large, Colon (56) (5) (55) (5) (52) (7)
Intestine Large, Cecum (54) (5) (54) (5) (53) (7)
Intestine Small, Duodenum (53) (5) (53) (5) (51) (7)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (54) (5) (53) (5) (51) (7)
Adenoma 1 (2%)
Liver (58) (5) (60) (5) (58) (7)
Hemangioma 1 (20%)
Hemangiosarcoma 2 (3%) 1 (2%) 1 (2%) 1 (14%)
Hepatocellular Carcinoma 11 (19%) 8 (13%) 4 (7%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 9 (16%) 1 (20%) 8 (13%) 9 (16%)
Hepatocellular Adenoma, Multiple 4 (7%) 2 (3%) 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%) 1 (14%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (3) (4) (1)
Carcinoma, Metastatic, Islets, Pancreatic 1 (33%)
Histiocytic Sarcoma 1 (100%)
Sarcoma, Metastatic, Skeletal Muscle 1 (25%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (25%)
Oral Mucosa (1)
Buccal, Squamous Cell Papilloma 1 (100%)
Pancreas (58) (5) (56) (5) (57) (7)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Page 2
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Forestomach 1 (2%)
Salivary Glands (58) (5) (60) (5) (58) (7)
Stomach, Forestomach (57) (5) (60) (5) (56) (7)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (57) (5) (58) (5) (56) (7)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (58) (5) (60) (5) (57) (7)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (58) (5) (58) (5) (58) (7)
Adenoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Adrenal Medulla (58) (5) (58) (5) (58) (7)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (58) (5) (56) (5) (57) (7)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (58) (4) (57) (5) (58) (7)
Pars Distalis, Adenoma 8 (14%) 5 (9%) 3 (5%)
Thyroid Gland (58) (5) (60) (5) (58) (7)
Follicular Cell, Adenoma 2 (3%) 4 (7%) 3 (5%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (4) (1) (1)
Histiocytic Sarcoma 1 (25%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (25%)
Mediastinum, Hemangiosarcoma 1 (25%)
Thoracic, Alveolar/Bronchiolar Carcinoma,
Page 3
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM - cont
Metastatic, Lung 1 (25%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (58) (4) (58) (5) (58) (7)
Cystadenoma 2 (3%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Luteoma 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Teratoma Benign 1 (2%)
Teratoma Malignant 1 (2%)
Uterus (58) (5) (60) (5) (58) (8)
Fibroma 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%) 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 1 (2%) 1 (13%)
Endometrium, Adenocarcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (57) (5) (60) (5) (57) (7)
Hemangiosarcoma, Metastatic, Tissue NOS 1 (2%)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Lymph Node (9) (12) (1) (11)
Iliac, Hemangiosarcoma 1 (11%)
Iliac, Sarcoma, Metastatic, Skeletal Muscle 1 (9%)
Pancreatic, Histiocytic Sarcoma 1 (8%)
Pancreatic, Sarcoma, Metastatic, Skeletal
Muscle 1 (9%)
Pancreatic, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (8%)
Renal, Histiocytic Sarcoma, Metastatic,
Uterus 1 (11%)
Renal, Sarcoma, Metastatic, Skeletal Muscle 1 (9%)
Lymph Node, Bronchial (50) (10) (57) (9) (58) (11)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Page 4
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mandibular (57) (7) (59) (7) (58) (10)
Lymph Node, Mesenteric (55) (5) (54) (5) (55) (7)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Lymph Node, Mediastinal (15) (28) (29) (3)
Histiocytic Sarcoma, Metastatic, Uterus 1 (7%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (4%)
Spleen (58) (5) (60) (5) (58) (7)
Fibrosarcoma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Tissue NOS 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Thymus (58) (5) (57) (5) (53) (6)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (57) (5) (59) (5) (58) (7)
Adenocarcinoma 1 (2%) 3 (5%)
Skin (58) (5) (60) (5) (58) (7)
Fibroma 1 (2%)
Fibrosarcoma 1 (2%)
Keratoacanthoma 1 (2%)
Pinna, Fibrosarcoma 2 (3%) 1 (2%)
Pinna, Squamous Cell Carcinoma 1 (2%)
Sebaceous Gland, Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (57) (5) (60) (5) (57) (7)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (1) (3) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
Hemangiosarcoma 1 (33%)
Hemangiosarcoma, Metastatic, Spleen 1 (33%)
Sarcoma 1 (33%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (58) (5) (60) (5) (58) (7)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (54) (4) (55) (4) (51) (6)
Epithelium, Squamous Cell Carcinoma 1 (2%)
Lung (58) (10) (59) (10) (58) (12)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 3 (5%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 7 (12%) 1 (2%) 2 (3%)
Hepatocellular Carcinoma, Metastatic 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 6 (10%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (8%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Nose (58) (10) (59) (10) (58) (12)
Hemangioma 1 (2%)
Trachea (57) (5) (57) (5) (56) (7)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1)
Adenoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (58) (10) (60) (10) (58) (12)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (8%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Urinary Bladder (56) (5) (55) (5) (57) (7)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(58) *(10) *(60) *(10) *(58) *(12)
Histiocytic Sarcoma 2 (3%) 2 (3%) 1 (2%) 1 (8%)
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(58) *(10) *(60) *(10) *(58) *(12)
Lymphoma Malignant 5 (9%) 7 (12%) 6 (10%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 2 39 36 3
Total Primary Neoplasms 69 2 55 48 3
Total Animals with Benign Neoplasms 27 2 22 20 1
Total Benign Neoplasms 35 2 25 26 1
Total Animals with Malignant Neoplasms 26 27 21 2
Total Malignant Neoplasms 34 30 22 2
Total Animals with Metastatic Neoplasms 7 12 2
Total Metastatic Neoplasm 18 37 7
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 20 60 20 60 20
Scheduled Sacrifice 1 18 2 18 2 18
Early Deaths
Moribund Sacrifice 27 25 1 25 1
Natural Death 6 2 8 1 8 1
Survivors
Terminal Sacrifice 26 25 25
Animals Examined Microscopically 59 12 59 11 58 12
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (56) (6) (50) (5) (53) (5)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Intestine Small, Duodenum (56) (5) (51) (5) (53) (6)
Adenoma 1 (2%)
Intestine Small, Jejunum (56) (5) (51) (5) (53) (6)
Intestine Small, Ileum (55) (5) (51) (5) (54) (6)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Liver (59) (7) (58) (6) (57) (7)
Fibrous Histiocytoma 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 10 (17%) 1 (14%) 15 (26%) 12 (21%) 1 (14%)
Hepatocellular Carcinoma, Multiple 2 (3%)
Hepatocellular Adenoma 11 (19%) 1 (14%) 8 (14%) 2 (33%) 11 (19%) 1 (14%)
Hepatocellular Adenoma, Multiple 2 (3%) 1 (2%) 3 (5%)
Hepatocholangiocarcinoma 1 (2%)
Mesentery (1)
Fibrous Histiocytoma, Metastatic, Liver 1 (100%)
Pancreas (59) (7) (58) (6) (56) (7)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Salivary Glands (59) (7) (58) (6) (57) (7)
Stomach, Glandular (59) (7) (58) (6) (55) (7)
Adenocarcinoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Tooth (4) (1) (4)
Odontoma 2 (50%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (59) (7) (58) (6) (58) (7)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (59) (7) (58) (6) (56) (7)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Capsule, Adenoma 2 (3%) 1 (2%)
Adrenal Medulla (58) (7) (58) (6) (54) (7)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Pheochromocytoma Complex 1 (2%)
Islets, Pancreatic (59) (7) (58) (6) (56) (7)
Adenoma 1 (2%) 1 (17%)
Pituitary Gland (56) (7) (57) (6) (53) (7)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (59) (7) (58) (6) (57) (7)
Follicular Cell, Adenoma 4 (7%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic 1 (100%)
Thoracic, Alveolar/Bronchiolar Carcinoma,
Metastatic 1 (100%)
Thoracic, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1)
Interstitium, Granular Cell Tumor NOS 1 (100%)
Epididymis (59) (7) (58) (6) (57) (7)
Fibrous Histiocytoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Leiomyoma 1 (2%)
Seminal Vesicle (59) (7) (58) (6) (57) (7)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Testes (59) (7) (58) (6) (57) (7)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (18) (1) (11) (2) (10) (1)
Axillary, Fibrosarcoma, Metastatic, Skin 1 (6%)
Pancreatic, Fibrous Histiocytoma, Metastatic,
Liver 1 (6%)
Lymph Node, Bronchial (39) (8) (53) (7) (53) (11)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Hepatocellular Carcinoma, Metastatic 1 (2%)
Lymph Node, Mesenteric (56) (7) (56) (6) (53) (7)
Adenocarcinoma, Metastatic, Stomach,
Glandular 1 (2%)
Fibrous Histiocytoma 1 (2%)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Lymph Node, Mediastinal (12) (3) (18) (3) (17) (5)
Spleen (59) (7) (57) (6) (55) (7)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Thymus (46) (7) (50) (5) (39) (7)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (59) (7) (56) (6) (57) (7)
Fibrosarcoma 1 (2%)
Fibrous Histiocytoma 1 (2%)
Pinna, Hemangiosarcoma 1 (2%)
Prepuce, Fibrous Histiocytoma 1 (2%)
Tail, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (59) (12) (58) (11) (56) (12)
Alveolar/Bronchiolar Adenoma 5 (8%) 3 (5%) 2 (4%)
Alveolar/Bronchiolar Adenoma, Two 1 (2%)
Alveolar/Bronchiolar Carcinoma 7 (12%) 2 (3%) 4 (7%)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 6 (10%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Pheochromocytoma Complex, Metastatic,
Adrenal Medulla 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (12) (58) (11) (57) (12)
Fibrous Histiocytoma, Metastatic, Liver 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Pelvis, Hemangiosarcoma 1 (2%)
Urinary Bladder (59) (7) (58) (7) (56) (7)
Leiomyosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(59) *(12) *(59) *(11) *(58) *(12)
Lymphoma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05107-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SUBSULFIDE Date: 05/19/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:48:32
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0MG/M3 0.0MG/M3 0.6MG/M3 0.6MG/M3 1.2MG/M3 1.2MG/M3
LUNG TOX LUNG TOX LUNG TOX
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 2 30 3 35 1
Total Primary Neoplasms 55 2 39 3 46 2
Total Animals with Benign Neoplasms 27 1 14 3 19 1
Total Benign Neoplasms 30 1 15 3 23 1
Total Animals with Malignant Neoplasms 20 1 23 20 1
Total Malignant Neoplasms 25 1 24 22 1
Total Animals with Metastatic Neoplasms 7 6 4
Total Metastatic Neoplasm 20 6 10
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------